» Articles » PMID: 32118013

Peripheral Blood-Based Biopsy for Breast Cancer Risk Prediction and Early Detection

Overview
Specialty General Medicine
Date 2020 Mar 3
PMID 32118013
Citations 17
Authors
Affiliations
Soon will be listed here.
Abstract

Among women, breast cancer (BC) is not only the most common cancer worldwide but also the leading cause of cancer death. Only 5-10% of breast cancer cases are attributed to inherited mutations (BRCA1, BRCA2, and other breast cancer susceptibility genes). Breast cancer incidence has been rising particularly in young women who are not eligible for mammography, and it has been acting as a burden especially in developing countries that lack screening and awareness programs. For this reason, research has shifted to use minimally invasive liquid biopsies especially blood-based biomarkers with potential value for breast cancer risk prediction and early detection. This mini-review will tackle the different blood-based biomarkers focusing mainly on circulating miRNA, circulating proteins, cell-free nucleic acids, methylation patterns, and exosomes. It also introduces the potential opportunities for the clinical use of these blood-based biomarkers for breast cancer risk prediction.

Citing Articles

Mir-21 and Mir-125b as theranostic biomarkers for epithelial ovarian cancer in Tunisian women.

Habel A, Nassar F, Itani M, Bouaziz H, Hadj-Ahmed M, Msheik Z Afr Health Sci. 2024; 23(2):256-264.

PMID: 38223583 PMC: 10782357. DOI: 10.4314/ahs.v23i2.29.


The impact of circulating protein levels identified by affinity proteomics on short-term, overall breast cancer risk.

Grassmann F, Malarstig A, Dahl L, Bendes A, Dale M, Thomas C Br J Cancer. 2023; 130(4):620-627.

PMID: 38135714 PMC: 10876928. DOI: 10.1038/s41416-023-02541-2.


An Overview of the Use of Precision Population Medicine in Cancer Care: First of a Series.

Yang J, Nittala M, Velazquez A, Buddala V, Vijayakumar S Cureus. 2023; 15(4):e37889.

PMID: 37113463 PMC: 10129036. DOI: 10.7759/cureus.37889.


Extracellular Vesicles in Breast Cancer: From Biology and Function to Clinical Diagnosis and Therapeutic Management.

Loric S, Denis J, Desbene C, Sabbah M, Conti M Int J Mol Sci. 2023; 24(8).

PMID: 37108371 PMC: 10139222. DOI: 10.3390/ijms24087208.


Prognostic and Predictive Biomarkers in Familial Breast Cancer.

Deb S, Chakrabarti A, Fox S Cancers (Basel). 2023; 15(4).

PMID: 36831687 PMC: 9953970. DOI: 10.3390/cancers15041346.


References
1.
Vu T, Nguyen T, Doan V, Vo L . Methylation Profiles of BRCA1, RASSF1A and GSTP1 in Vietnamese Women with Breast Cancer. Asian Pac J Cancer Prev. 2018; 19(7):1887-1893. PMC: 6165660. DOI: 10.22034/APJCP.2018.19.7.1887. View

2.
Wendler F, Favicchio R, Simon T, Alifrangis C, Stebbing J, Giamas G . Extracellular vesicles swarm the cancer microenvironment: from tumor-stroma communication to drug intervention. Oncogene. 2016; 36(7):877-884. DOI: 10.1038/onc.2016.253. View

3.
Najjar H, Easson A . Age at diagnosis of breast cancer in Arab nations. Int J Surg. 2010; 8(6):448-52. DOI: 10.1016/j.ijsu.2010.05.012. View

4.
Shan M, Yin H, Li J, Li X, Wang D, Su Y . Detection of aberrant methylation of a six-gene panel in serum DNA for diagnosis of breast cancer. Oncotarget. 2016; 7(14):18485-94. PMC: 4951303. DOI: 10.18632/oncotarget.7608. View

5.
Swellam M, Abdelmaksoud M, Sayed Mahmoud M, Ramadan A, Abdel-Moneem W, Hefny M . Aberrant methylation of APC and RARβ2 genes in breast cancer patients. IUBMB Life. 2015; 67(1):61-8. DOI: 10.1002/iub.1346. View